Published in Cancer Weekly, July 5th, 2005
In the National Cancer Research Institute, U.K. (NCRI) multicenter study of older patients with AML who were unsuitable for intensive chemotherapy, the overall response for clofarabine was 67%. Eleven (42%) patients in this trial had abnormal cytogenetics, and of these five (45%) achieved a complete response (CR) with clofarabine. For patients with normal cytogenetic profile, the CR was 73%. In addition, the median duration of remission in patients responding to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.